AU2025204331A1 — Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor

USPTO Abstract

#$%^&*AU2025204331A120250626.pdf##### PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor I-((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo [3,4-d]pyrimidin- l-yl)piperidin-l-yl)prop-2-en-I-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract FIG. 1 30 Formulation A 25 Formulation B Formulation C Formulation D 20 15 10 5 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor I-((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazole [3,4-d]pyrimidin- 1-yl)piperidin-l-yl)prop-2-en-I-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. 20 25 20 43 31 11 J un 2 02 5 P H A R M A C E U T I C A L F O R M U L A T I O N S O F B R U T O N ' S T Y R O S I N E 1 1 J u n 2 0 2 5 K I N A S E I N H I B I T O R A b s t r a c t F I G . 1 3 0 F o r m u l a t i o n A 2 0 2 5 2 0 4 3 3 1 2 5 F o r m u l a t i o n B Mean Ibrutinib Plasma Concentration (ng/mL) F o r m u l a t i o n C F o r m u l a t i o n D 2 0 1 5 1 0 5 0 6 1 2 1 8 2 4 N o m i n a l T i m e P o s t - D o s e ( h ) D e s c r i b e d h e r e i n a r e p h a r m a c e u t i c a l f o r m u l a t i o n s o f B r u t o n ' s t y r o s i n e k i n a s e ( B t k ) i n h i b i t o r I - ( R ) - 3 - ( 4 - a m i n o - 3 - ( 4 - p h e n o x y p h e n y l ) - I H - p y r a z o l o [ 3 , 4 - d ] p y r i m i d i n - 1 - y l ) p i p e r i d i n - l - y l ) p r o p - 2 - e n - I - o n e . A l s o d i s c l o s e d a r e m e t h o d s o f u s i n g t h e B t k i n h i b i t o r , a l o n e o r i n c o m b i n a t i o n w i t h o t h e r t h e r a p e u t i c a g e n t s , f o r t h e t r e a t m e n t o f a u t o i m m u n e d i s e a s e s o r c o n d i t i o n s , h e t e r o i m m u n e d i s e a s e s o r c o n d i t i o n s , c a n c e r , i n c l u d i n g l y m p h o m a , a n d i n f l a m m a t o r y d i s e a s e s o r c o n d i t i o n s . P H A R M A C E U T I C A L F O R M U L A T I O N S O F B R U T O N ' S T Y R O S I N E 1 1 J u n 2 0 2 5 K I N A S E I N H I B I T O R A b s t r a c t F I G . 1 3 0 F o r m u l a t i o n A 2 0 2 5 2 0 4 3 3 1 2 5 F o r m u l a t i o n B Mean Ibrutinib Plasma Concentration (ng/mL) F o r m u l a t i o n C F o r m u l a t i o n D 2 0 1 5 1 0 5 0 6 1 2 1 8 2 4 N o m i n a l T i m e P o s t - D o s e ( h ) D e s c r i b e d h e r e i n a r e p h a r m a c e u t i c a l f o r m u l a t i o n s o f B r u t o n ' s t y r o s i n e k i n a s e ( B t k ) i n h i b i t o r I - ( R ) - 3 - ( 4 - a m i n o - 3 - ( 4 - p h e n o x y p h e n y l ) - I H - p y r a z o l o [ 3 , 4 - d ] p y r i m i d i n - 1 - y l ) p i p e r i d i n - l - y l ) p r o p - 2 - e n - I - o n e . A l s o d i s c l o s e d a r e m e t h o d s o f u s i n g t h e B t k i n h i b i t o r , a l o n e o r i n c o m b i n a t i o n w i t h o t h e r t h e r a p e u t i c a g e n t s , f o r t h e t r e a t m e n t o f a u t o i m m u n e d i s e a s e s o r c o n d i t i o n s , h e t e r o i m m u n e d i s e a s e s o r c o n d i t i o n s , c a n c e r , i n c l u d i n g l y m p h o m a , a n d i n f l a m m a t o r y d i s e a s e s o r c o n d i t i o n s .